Renaissance Technologies’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,000
| Closed | -$300K | – | 3759 |
|
|
2024
Q3 | $300K | Sell |
3,000
-15,200
| -84% | -$1.53M | ﹤0.01% | 2983 |
|
|
2024
Q2 | $1.53M | Sell |
18,200
-28,900
| -61% | -$2.3M | ﹤0.01% | 2049 |
|
|
2024
Q1 | $3.44M | Sell |
47,100
-19,200
| -29% | -$1.42M | 0.01% | 1659 |
|
|
2023
Q4 | $4.74M | Buy |
66,300
+10,600
| +19% | +$626K | 0.01% | 1387 |
|
|
2023
Q3 | $3.34M | Buy |
55,700
+13,300
| +31% | +$875K | 0.01% | 1535 |
|
|
2023
Q2 | $3.06M | Buy |
42,400
+12,600
| +42% | +$945K | ﹤0.01% | 1730 |
|
|
2023
Q1 | $2.19M | Buy |
29,800
+5,300
| +22% | +$377K | ﹤0.01% | 1976 |
|
|
2022
Q4 | $1.64M | Sell |
24,500
-2,270
| -8% | -$148K | ﹤0.01% | 2204 |
|
|
2022
Q3 | $1.44M | Sell |
26,770
-2,074
| -7% | -$122K | ﹤0.01% | 2266 |
|
|
2022
Q2 | $1.6M | Buy |
+28,844
| New | +$1.64M | ﹤0.01% | 2357 |
|
|
2020
Q3 | – | Sell |
-217,277
| Closed | -$15.2M | – | 3539 |
|
|
2020
Q2 | $15.2M | Sell |
217,277
-744,433
| -77% | -$47.2M | 0.01% | 980 |
|
|
2020
Q1 | $43.6M | Sell |
961,710
-675,256
| -41% | -$38.3M | 0.04% | 430 |
|
|
2019
Q4 | $107M | Sell |
1,636,966
-317,755
| -16% | -$21.2M | 0.08% | 262 |
|
|
2019
Q3 | $121M | Sell |
1,954,721
-98,414
| -5% | -$6.18M | 0.1% | 217 |
|
|
2019
Q2 | $146M | Sell |
2,053,135
-216,245
| -10% | -$15.9M | 0.13% | 169 |
|
|
2019
Q1 | $178M | Sell |
2,269,380
-104,373
| -4% | -$7.91M | 0.16% | 141 |
|
|
2018
Q4 | $201M | Buy |
2,373,753
+1,164,740
| +96% | +$124M | 0.22% | 82 |
|
|
2018
Q3 | $207M | Buy |
1,209,013
+369,852
| +44% | +$55.8M | 0.21% | 91 |
|
|
2018
Q2 | $108M | Buy |
839,161
+255,037
| +44% | +$28.5M | 0.12% | 183 |
|
|
2018
Q1 | $60.2M | Buy |
584,124
+504,936
| +638% | +$49.9M | 0.07% | 367 |
|
|
2017
Q4 | $6.76M | Buy |
+79,188
| New | +$6.86M | 0.01% | 1620 |
|
|
2017
Q3 | – | Sell |
-125,185
| Closed | -$9.48M | – | 3287 |
|
|
2017
Q2 | $9.48M | Sell |
125,185
-36,902
| -23% | -$2.58M | 0.01% | 1306 |
|
|
2017
Q1 | $10.7M | Buy |
+162,087
| New | +$10.7M | 0.02% | 1187 |
|
|
2016
Q3 | – | Sell |
-185,954
| Closed | -$13.8M | – | 3423 |
|
|
2016
Q2 | $13.8M | Sell |
185,954
-1,276
| -0.7% | -$94.7K | 0.03% | 934 |
|
|
2016
Q1 | $12.5M | Sell |
187,230
-92,173
| -33% | -$5.6M | 0.02% | 977 |
|
|
2015
Q4 | $18.9M | Buy |
279,403
+163,666
| +141% | +$10.1M | 0.04% | 583 |
|
|
2015
Q3 | $6.18M | Sell |
115,737
-38,302
| -25% | -$2.32M | 0.01% | 1234 |
|
|
2015
Q2 | $9.7M | Buy |
+154,039
| New | +$8.4M | 0.02% | 979 |
|
|
2014
Q3 | – | Sell |
-61,866
| Closed | -$2.4M | – | 2880 |
|
|
2014
Q2 | $2.4M | Buy |
+61,866
| New | +$2.51M | 0.01% | 1636 |
|
Other funds holding LGND
CAM
SIMG
CC
Renaissance Technologies's LGND Position: Q4 2024 in Review
Renaissance Technologies sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 3,000 shares — an estimated $300K sold.
Renaissance Technologies first reported a position in LGND in Q2 2014 and held it in 29 quarters. The position peaked at $207M in Q3 2018. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.
- Renaissance Technologies reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Renaissance Technologies sold 3,000 Ligand Pharmaceuticals shares in Q4 2024, an estimated $300K.
- Renaissance Technologies first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 29 quarters.
- Renaissance Technologies's Ligand Pharmaceuticals position peaked at $207M in Q3 2018.
- 258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.
Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.